Here are Tuesday's biggest analyst calls: Nvidia, Apple, Microsoft, Rivian, Amazon, CrowdStrike & more

Bank of America reinstated Qualcomm as Underperform with a $145 price objective, while multiple firms upgraded or initiated Buy on names including Teladoc (Deutsche Bank), Rivian (Cowen), Gilead (Jefferies), Intuit (Redburn), CrowdStrike (Morgan Stanley upgrade to Overweight) and B. Riley initiating Strategy/MSTR as Buy; Wolfe raised Amazon's target to $255 and BofA reiterated Nvidia ahead of the Mar‑16 GTC. TD Cowen downgraded Novo Nordisk to Hold from Buy. These are largely stock‑specific analyst moves that are mildly positive in aggregate and likely to move individual equities (order of ~1–3%) rather than the broader market.

Analysis

The research flow this morning reflects a bifurcation in secular demand: on one side, compute- and cloud-driven AI spending is compounding TAM for hyperscalers and security platforms; on the other, mature mobile and obesity franchises are entering multi-year margin and growth normalization. That divergence is likely to widen capital allocation and R&D priorities across the semiconductor and software supply chains, concentrating incremental capex into datacenter accelerators, networking, and telemetry rather than handset RF and legacy SoC lines. Expect foundries, memory and infrastructure OEMs to capture a disproportionate share of next‑two‑year incremental gross margin versus mid-market mobile suppliers.

For software and security, the knock-on is that seat-based and telemetry-driven monetization accelerates ARR visibility and lowers churn, meaning multiples should re-rate for companies that convert agent telemetry into adjacent modules. Conversely, businesses with single-product linear growth — or those facing high-margin branded competition in biopharma — will face multiple compression unless they deliver clear new revenue levers. The timeline for material re-rating is 6–18 months as enterprises complete procurement cycles and large deals lap through quarter cadences.

From a risk perspective, macro and policy shocks remain the primary reversals: sustained higher real rates or regulatory action (privacy, AI export controls, healthcare pricing) can quickly re-price optionality. Short-term event risk around product launches or earnings will create volatility windows to hedge or scale, but the structural trade is the concentration of value into AI infrastructure, enterprise software moats, and optional balance-sheet plays — not broad-based semiconductors or single-label consumer winners.

Key Decisions for Investors

• Long NVDA exposure via a defined-risk options spread (9–12 months): buy-dated call spread sized 2–3% of fund NAV to capture continued AI infrastructure re-rating; target 2.5x payoff, stop-loss at 40% of premium to limit capital at risk.
• Pair trade: long MSFT (6–12 months) / short QCOM (6–12 months) equal-dollar notional. Rationale: tilt to enterprise AI spend and platform monetization vs normalization in handset SoC growth; target outperformance of 20–30% and cap max drawdown to 6% NAV each leg with 6% stop-loss.
• Buy CRWD shares or 12–18 month LEAPS (~1–2% NAV): exposure to rising telemetry + module uptake. Take profits at +50–60% or if ARR growth decelerates below 20% YoY; hedge with a 6–9 month bought put if implied vol is cheap.
• Event/catalyst small-cap position: initiate a tactical long in TDOC-sized 0.5–1% NAV with a 6–12 month horizon to capture potential strategic consolidation value; absolute downside protected allocation and sell half position on +100% or if gross margin fails to expand within two quarters.